Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial
Authors' conclusion
In our study MBDA score in baseline was not predictive of relapse, discontinuation of TNFi in patients with long-standing RA patients tapering TNFi.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in remission who completed STRASS and had baseline serum samples available for multi-biomarker disease activity (MBDA) testing
- Participants
- 64 vs 73
- Comparison
- Baseline MBDA score in patients who relapsed vs did not relapse, in spacing and maintenance arms
- S-armn = 64
- M-armn = 73reference
- Primary endpoint
- Ability of baseline MBDA score to predict relapse at any time during the 18 months following initiation of TNFi tapering
- Follow-up
- 18 months
Methodological detailspost-hoc analysis, multicentre, equivalence
- Post-hoc analysis
- Multicentre
- Equivalence
Primary result
As reported in the abstract
Mean baseline MBDA score, relapse vs no relapse
- M-arm: relapsed vs not relapsed, mean MBDA score 32.5 vs 27.2
- p=0.053
- S-arm: relapsed vs not relapsed, MBDA score 27 vs 26.2 (no difference)
- p=0.57
Secondary outcomes
- TNF-inhibitor (TNFi) discontinuation (S-arm) · Month 18
- 21.3% · 13
Radiographic progression (both arms, n=9): discriminative value of baseline MBDA score · month 18
- AUC
- 0.558
- Not correlated with MBDA score at baseline
Original publication
Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial. Clin Exp Rheumatol. Published 9 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →